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Abstract Proteasomes are the major protein-degrading com-
plexes in the cytosol and regulate many cellular processes. To
examine the functional importance of the MC14/MECL-1
proteasome active site subunits, cell lines expressing a catalyti-
cally inactive form of MECL-1 were established. Whereas
mutant MECL-1 was readily incorporated into cytosolic
proteasomes, replacing the constitutive MC14 subunit, removal
of the prosequence was incomplete indicating that its processing
required autocatalytic cleavage. Functional analyses showed that
the absence of the MC14/MECL-1 active sites abrogated
proteasomal trypsin-like activity, but did not affect other
catalytic activities. Our data demonstrate a conservation of
cleavage specificity between mammalian and yeast proteasomes.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Proteasomes are enzyme complexes abundant in the cytosol
and probably also the nucleus of all eukaryotic cells (for re-
view see [1,2]). They play a central role in the cytosolic pro-
teolysis of misfolded proteins and of many short-lived and
long-lived proteins. Moreover, proteasomes regulate multiple
cellular processes such as cell cycle control, transcription fac-
tor activation and also MHC class I antigen processing in
higher eukaryotes.
Proteasomes consist of a 20S catalytic core which associates
with regulatory particles, e.g. PA28 or 11S and the 19S com-
plex or PA700 [1,2]. Binding to the 19S complex confers pro-
tein degrading activity and substrate speci¢city on the 20S
core which by itself lacks the ability to degrade proteins,
probably due to limited access to the proteolytic channel [3].
One well characterized speci¢city of 19S is that for polyubi-
quitin-conjugated substrates, which are bound by at least one
but probably several of the 19S subunits [4]. The PA28 regu-
lator is selectively expressed in higher eukaryotes and enhan-
ces the capacity of proteasomes to degrade antigens into pep-
tides that bind to MHC class I molecules [5,6]. In PA28-
containing cells, both 19S and PA28 can bind to the 20S
core, solely or simultaneously [7], likely resulting in a di¡erent
tuning of 20S activity.
The 20S catalytic core consists of four heptameric rings.
The outer rings contain the K-subunits K1^K7, the two inner
rings the L-subunits L1^L7 of which three, L1 or N, L2 or
MC14 (mouse) or Z (human), and L5 or MB1, exert catalytic
activity [1,8]. Remarkably, in interferon Q (IFNQ)-induced cells
of higher eukaryotes three additional catalytically active sub-
units, LMP2 (iL1), MECL-1 (iL2) and LMP7 (iL5), are tran-
scribed which replace the constitutive subunits N, MC14 or Z
and MB1 in the proteasome complex, resulting in the forma-
tion of so called immunoproteasomes [9,10].
Since proteasome substrate choice, kinetics of protein deg-
radation and the precise cleavages mediated are of extreme
importance to many cellular processes, e.g. MHC class I anti-
gen processing, knowledge of the proteolytic mechanisms of
proteasomes is essential. Using tri- and tetrapeptide sub-
strates, the substrate speci¢city of the active site subunits
has been determined, though with inconsistent results. While
several groups showed that replacement of constitutive for
IFNQ-induced subunits enhanced the trypsin-like (T-L) and
chymotrypsin-like (ChT-L) activity of proteasomes, opposite
results were obtained by others [11^15]. Recently, mutant sub-
units with an inactivated catalytic site were used to further
elucidate substrate speci¢cities. In mouse cells, substitution of
N by inactive LMP2 T1A was shown to abrogate cleavages
after acidic residues [16], con¢rming earlier studies ascribing
the proteasomal peptidyl glutamyl hydrolyzing (PGPH) activ-
ity to the N subunit [9]. In yeast, a detailed analysis of pro-
teasomes with di¡erent inactive catalytic sites led to the as-
signment of PGPH activity to L1, T-L activity to L2 and
ChT-L activity to each of the three catalytic subunits
[17,18]. The cleavage site preferences determined with tri-
and tetrapeptides appeared to correspond with proteasomal
site usage in the yeast enolase 1 protein, though the much
broader speci¢cities of the L1 and L2 active centers did not
in every case correspond to the preferences deduced from tri-
and tetrapeptides [19].
We and others [20^22] recently described the identi¢-
cation of MC14 or Z (L2) as the third subunit which is ex-
changed for an induced homologue, MECL-1 (iL2), in IFNQ-
induced cells. To start to elucidate the function of the MC14/
MECL-1 subunits, we used a catalytically inactive (T1A)
form of MECL-1 to replace MC14 in mouse ¢broblast cells.
Testing the peptide hydrolyzing activity of MECL1 T1A
proteasomes we noticed a complete abrogation of T-L activ-
ity, indicating that MC14 is solely responsible for the T-L
activity of mouse proteasomes. On the basis of these and
previous data, we conclude that despite the evolutionary dis-
tance between yeast and murines the cleavage speci¢city of
proteasomes, a major regulatory cellular complex, is con-
served.
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2. Materials and methods
2.1. DNA constructs
To generate mMECL-1 T1A, the base triplet ACT encoding Thr-1
in mMECL-1 wild type (wt) cDNA was exchanged for a codon en-
coding alanine (GCT) by polymerase chain reaction (PCR)-based mu-
tagenesis. The following synthetic oligonucleotides were used: primer
1, 5P-GCAGGCGAATTCATGCTGAAGCAGGCAGTG-3P contain-
ing an EcoRI restriction site and the ATG translation initiation site;
primer 2, 5P-GCACGCAAGACCGGGGCTACCATCGCGGGGCT-
T-3P (forward) and primer 3, 5P-AAGCCCCGCGATGGTAGCCCC-
GGTCTTGCGTGC-3P (reverse), introducing the A to G point muta-
tion in the codon encoding Thr-1; primer 4, 5P-CTGTTTAGA-
TCTTCATTCCACCTCCATGGC-3P containing the translation stop
site and a BglII restriction site. Primer combinations 1 and 3 and 2 and
4 were used to generate an MECL-1 T1A 5P and an MECL-1 T1A 3P
fragment from mMECL-1 wt cDNA. The two fragments were an-
nealed in a consecutive PCR, the product was ampli¢ed with primers
1 and 4 and cloned into the eukaryotic expression vector pSG5.
2.2. Cell lines and transfections
Mouse ¢broblast B8 cells, B8 LMP2+LMP7 (BC27H7) [12] and B8
LMP2+LMP7+MECL-1 (B27M.2) transfectant cells [23] were grown
in Iscove’s modi¢ed Dulbecco’s medium supplemented with 10% fetal
calf serum (FCS), 2 mM L-glutamine, penicillin, streptomycin, 0.02%
2-mercaptoethanol, 250 Wg/ml G418, and 400 Wg/ml hygromycin for
LMP transfectant cells. T2 LMP2+LMP7 transfectant cells (T27.10)
[24] were grown in RPMI with 10% FCS, L-glutamine, penicillin,
streptomycin and 1 mg/ml G418. The pSG5 mMECL-1 T1A expres-
sion construct was transfected into T27.10 cells using electroporation
[26] and in BC27H7 cells using calcium phosphate precipitation.
Transfected cells were plated under cloning conditions and selected
with 200 Wg/ml hygromycin and 2.5 Wg/ml puromycin for T2 and B8
transfectant cells respectively.
2.3. Western blot analysis
Expression of mMECL-1 T1A was tested by Western blot analysis
as described [23].
2.4. Proteasome puri¢cation and NEPHGE-, IEF-PAGE
Puri¢cation of 20S proteasomes from cell lines was performed as
described [12,25]. Puri¢ed TCA-precipitated proteasomes (60 Wg) were
separated by two-dimensional NEPHGE-PAGE or IEF-PAGE [20].
Gels were stained with 0.2% Coomassie brilliant blue and the protea-
some subunits were assigned as described [20] or identi¢ed by micro-
sequencing [26]. Alternatively, the separated proteins were transferred
to Immobilon P membrane and probed with mMECL-1-speci¢c rab-
bit antiserum.
2.5. Peptide digestion assays
The cleavage properties of the 20S proteasomes were tested against
the £uorogenic peptides Bz-VGR-AMC, Suc-LLVY-AMC, and
Z-LLE.LNA (Bachem, Heidelberg, Germany). Peptide substrates
were diluted in assay bu¡er (50 mM Tris-HCl pH 7.5, 25 mM KCl,
10 mM NaCl, 1 mM dithiothreitol, 0.1 mM EDTA) and incubated
with 200 ng 20S proteasomes at the concentrations speci¢ed in the
¢gure legends, for 1 h at 37‡C. Fluorescence emission was measured
at 460 nm for free AMC groups (excitation 390 nm) and at 405 nm
for free LNa groups (excitation 355 nm).
3. Results and discussion
To examine the functional importance of the MC14 (or Z)/
MECL-1 pair of proteasome subunits, the mouse MECL-1
(mMECL-1) sequence was modi¢ed to encode an alanine in-
stead of the active site threonine at position 1 and resulting
construct was transfected into LMP2+7 containing human
lymphoblast T2 cells (T27.10). T27.10 cells were chosen be-
cause the presence of LMP2 in particular and to a lesser
extent of LMP7 should support the incorporation of newly
transfected mMECL-1 into the proteasome complex
[10,23,26]. Positive transfectant clones were identi¢ed by im-
munoblot analysis with a mMECL-1-speci¢c polyclonal rabbit
antiserum. Surprisingly, this procedure revealed three bands
for MECL-1 in transfectant cells, as shown for a representa-
tive clone in Fig. 1A (lane 1). Based on migrational behavior,
we identi¢ed the upper band as the unprocessed mMECL-1
T1A precursor protein [23]. The second prominent band mi-
grating slightly more slowly than the MECL-1 wt form (lane
2) most likely represents a partially processed form of
mMECL-1 T1A (see below), whereas the faint 29 kDa band
corresponding in molecular weight (MW) to the mMECL-1
wt subunit (lane 2) must result from cross-reaction of the
antiserum with the human MECL-1 (hMECL-1) subunit
which is endogenously expressed in T2 cells (see below).
As reported for LMP2 T1A [25], the inactivation of the
Thr-1 catalytic center prevented autocatalytic cleavage of the
LMP2 prosequence at the Gly 31 Thr +1 site. A second
processing event within the prosequence was not prevented
suggesting that the cleavage of proteasomal propeptides might
be achieved by a two-step mechanism. To further characterize
the in£uence of the T1A mutation in mMECL1, 20S protea-
somes were puri¢ed of T27.10 mMECL-1T1A transfectant
cells and of T27.10 cells for comparison, and separated by
two-dimensional IEF-PAGE (Fig. 2A,B). The position of
mMECL-1 T1A in the Coomassie-stained gel of T27.10
mMECL-1 T1A proteasomes (Fig. 2B) was established by
immunoblotting with mMECL1-speci¢c antibodies (Fig. 2C).
N-terminal sequencing of the respective spots revealed the
Fig. 1. Incorporation of catalytically inactive mMECL-1 T1A into 20S proteasomes of T2 (A) and B8 (B) transfectant cells. T2 and B8 cells
were transfected with an mMECL-1 T1A expression vector as described in Section 2. Cellular lysates of transfectant clones were separated by
SDS-PAGE and probed with a mMECL-1-speci¢c polyclonal rabbit antiserum. Controls included lysates of B8 cells that were treated with
IFNQ for 3 days (A) and of B8 and B8 LMP2+7+mMECL-1 wt cells (B). MECL-1, MECL-1 T1A and the precursor form (pMECL-1) are in-
dicated. Molecular weight markers in kDa are shown on the left.
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presence of mMECL-1 T1A and identical N-termini in the
two most prominent spots, thus, MECL-1 T1A exists in at
least two isoforms which have di¡erent charges. Both iso-
forms migrated with an MW corresponding to that of the
middle MECL-1 signal in Fig. 1A. Similarly to the partially
processed product of the LMP2 T1A protein [25], we found
that autocatalytic cleavage of the mMECL1 propeptide was
prevented at the conserved Gly Thr site and that an additional
processing event had occurred, at position 318 within the
prosequence (Fig. 2D). Apart from transfected mMECL-1
T1A also the endogenous hMECL-1 wt form is visible in
the Coomassie gel (Fig. 2A,B). Thus, due to the presence of
LMP2 in the cell line used, exogenous mMECL1 T1A and the
endogenous hMECL1 are incorporated e⁄ciently into the ma-
ture proteasome complex. Of note, the unprocessed precursor
mMECL-1 T1A protein is not incorporated into the protea-
some complex and is therefore not present in the two-dimen-
sional gel.
Interestingly, an additional protein spot was seen in protea-
somes containing mMECL1 T1A, not present in proteasomes
from T27.10 cells (Fig. 2A,B). Microsequencing identi¢ed this
spot as subunit N3 containing an additional amino acid, Arg,
at the N-terminus (Fig. 2D), explaining the charge shift of this
spot with respect to correctly processed N3 (Fig. 2A). These
observations suggest that the inactivation of MECL-1 in£u-
ences correct processing of its neighbor across the two con-
tacting L-rings, N3. Our data are consistent with results ob-
tained upon inactivation of Pup1 in yeast proteasomes [17].
Thus, the processing mechanism of eukaryotic proteasomes
appears to be a conserved process.
Due to the presence of hMECL-1 in T27.10 mMECL-1T1A
cells mMECL-1 T1A competes with endogenous hMECL-1
for incorporation. Therefore, the resulting proteasome popu-
lation did not contain su⁄cient amounts of mMECL-1T1A,
which would allow the analysis of enzymatic activities of the
MC14/MECL-1 active sites. To allow such an analysis,
mMECL-1 T1A cDNA was transfected into B8 LMP2+7
(BC27H7) mouse ¢broblast cells cells which have low levels
of endogenous mMECL-1 [11]. Like observed in T2 cells,
mMECL-1 T1A expressed in BC27H7 cells migrated as a
31 kDa protein (Fig. 1B, lanes 3^5), indicating that this sub-
unit was incorporated into the 20S proteasomes of the trans-
fectant clones but was processed incompletely. Endogenous
mMECL-1 wt was barely detectable, like in the B8 parental
cell line (Fig. 1B, lane 1, Fig. 3E). Thus, the established clones
express mMECL-1 T1A at high levels and lack any signi¢cant
amounts of endogenous mMECL-1.
To examine the e⁄ciency of MC14 for mMECL-1 T1A
exchange, proteasomes were puri¢ed of B8 LMP2+7+
mMECL-1 T1A clone 7 (B8.27.MT1A) cells and of B8+
LMP2+LMP7+mMECL-1 (B27M.2) cells as a control. Coo-
massie-stained two-dimensional IEF-PAGE gels (Fig. 3)
showed the presence of MC14 and mMECL-1 in B27M.2
proteasomes (Fig. 3B). While a spot representing MC14 was
visible in proteasomes of B8.27.MT1A cells, mMECL-1 wt
was not detected (Fig. 3A). Instead, an additional spot was
observed which on the basis of its MW and isoelectric point
(IP) was identi¢ed as mMECL-1 T1A). Further immunoblot
analyses (not shown) revealed the presence of only minor
quantities of mMECL-1 T1A, precluding N-terminal sequenc-
ing, at more than one position in the B8.27.MT1A Coomassie
gel as observed for T2 proteasomes (Fig. 2). The intensities of
the visible mMECL-1 T1A spot and MC14 spot in Fig. 3A
suggest roughly equal incorporation rates for the two subunits
in B8.27.MT1A proteasomes. Therefore, the exchange e⁄-
ciency of MC14 for mMECL-1 T1A is similar to that ob-
served for mMECL-1 wt and MC14 in B27M.2 cells (Fig. 3B).
The subunit composition of proteasomes of B8.27.MT1A,
B27M.2 and of B8 cells which in£uences enzymatic activity
(see below) was further characterized by two-dimensional
NEPHGE-PAGE (Fig. 3D^F). Proteasomes puri¢ed from
B8 cells did not contain any substantial amounts of LMP2
and LMP7 nor of mMECL-1 (Fig. 3E) as was already pre-
viously shown by Boes et al. and Groettrup et al. [11,23] and
is demonstrated in Fig. 1. Both proteasomes of B27M.2 and
of B8.27.MT1A cells showed an e⁄cient replacement of N and
MB1 for LMP2 and LMP7. In the context of these experi-
ments in particular the exchange of N versus LMP2 is of
importance since LMP2 also determines the incorporation
e⁄ciency of MECL-1 [23]
To examine the function of the MECL-1 catalytic site, we
compared the peptide hydrolyzing activities of the three pro-
Fig. 2. Incorporation of mMECL-1 T1A into 20S proteasomes of
T2 transfectant cells. T27.10 cells expressing mMECL-1 T1A were
expanded and 20S proteasomes were puri¢ed as described [25]. Pro-
teasome aliquots from T27.10 (A) and from T27.10-mMECL-1 T1A
(B) of 60 Wg were separated by two-dimensional IEF/SDS-PAGE
and the subunits were visualized with Coomassie brilliant blue (A,
B). The positions of relevant L-subunits are indicated in A. Spots
containing misprocessed mMECL-1 and N32 present in mutant
proteasomes are indicated in B. mMECL-1 T1A-containing protea-
somes were additionally blotted to Immobilon P and probed with
an anti-mMECL-1 antiserum (C). The N-termini of mMECL-1 T1A
and of N3 were identi¢ed by Edman degradation as described [25].
The sequences obtained are underlined in the mMECL1 and N3
prosequences, given in D. Large arrows indicate the actual cleavage
sites of these proteasome subunits in the mutant cell line, while
small arrows designate the expected cleavage site in wild type sub-
units.
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teasome populations shown in Fig. 3. Consistent with our
earlier observations [11,12,24], we found that the incorpora-
tion of the IFNQ-inducible subunits reduced the T-L, PGPH
and ChT-L activities of B8 proteasomes as measured using the
Bz-VGR-AMC, Z-LLE-LNA, and SUC-LLVY-AMC sub-
strates respectively (Fig. 4). It may be worth mentioning
that in particular the PGPH activity is most drastically re-
duced due to the presence of LMP2. Remarkably, while pro-
teasomes containing mMECL-1 T1A instead of mMECL-1
converted the SUC-LLVY-AMC and Z-LLE-LNA peptides
to about the same extent as wild type immunoproteasomes,
mMECL-1 T1A proteasomes failed to hydrolyze the Bz-
VGR-AMC tripeptide. Therefore, we infer that the T-L activ-
ity of mammalian proteasomes, as de¢ned with short peptide
substrates, is largely mediated by the MC14/MECL-1 catalytic
sites. Also, the MC14/MECL-1 subunits do not play any sig-
ni¢cant role in the hydrolysis of hydrophobic or acidic sub-
strates. Interestingly, these data corroborate previous ¢ndings
by the groups of Wolf and Rammensee [17,18], showing that
the L2 catalytic site of yeast proteasomes is to a large extent
responsible for T-L activity. Likewise, we previously showed
that mammalian N exerts the proteasomal PGPH activity,
consistent with the recent data of cited investigators who as-
signed this activity to the yeast L1 subunit [16]. From these
Fig. 3. Subunit composition of 20S proteasomes of B8.27.MT1A (A, C), B27M.2 (B, D) and of B8 (E) cells. 20S proteasomes were puri¢ed of
B8.27.MT1A (A, C), B27M.2 (B, D) and of B8 (E) cells and subjected to two-dimensional IEF-PAGE (A, B) to analyze the exchange of
MC14 for MECL-1 or mMECL-1 T1A or NEPHGE-PAGE to analyze the N/LMP2 or MB1/LMP7 exchange (C^E). Separated proteins were
stained with Coomassie blue. Proteasome subunits were assigned on the basis of their migrational behavior as indicated [20].
Fig. 4. Replacement of MC14 by mMECL T1A inhibits the T-L activity of 20S proteasomes. Peptide cleavage activities were assayed by
incubating speci¢ed substrates with 200 ng puri¢ed 20S proteasomes in a volume of 100 Wl for 60 min at 37‡C. Release of the £uorescent
groups was measured with a spectro£uorometer at 355 nm excitation/405 nm emission (Z-LLE-LNA) or 390 nm excitation/460 nm emission
(SUC-LLVY-AMC, Bz-VGR-AMC) and plotted on the y-axis. Mean values of duplicate wells are plotted.
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biochemical experiments we infer that the proteolytic activities
of the yeast and mammalian proteasomal catalytic centers are
conserved, a conclusion which is in agreement with the struc-
tural data obtained from the yeast proteasome X-ray structure
[3].
Since the ratio between MC14 and mMECL-1 T1A in the
isolated proteasome population of B8.27.MT1A cells was es-
timated to be roughly 1:1 (Fig. 3A), the observed complete
abolition of one of the proteasome-hydrolyzing activities was
unexpected. These data can be interpreted such that protea-
some mixed populations with mMECL-1 T1A in one and
MC14 in the other L-ring are formed, whereby we propose
that the inactive mutant subunit may a¡ect the activity of the
second homologous site. Such an interpretation is supported
by the almost complete elimination of the T-L activity in the
B8.27.MT1A mutant which would not be expected if consid-
erable amounts of proteasomes containing only MC14 were
present in our preparation. Indeed, other investigators using
intact cellular systems have demonstrated the formation of
proteasome mixed populations containing both constitutive
proteasome subunits and their induced homologues [21,27].
Further experiments using tagged proteasome subunits to pu-
rify proteasome subpopulations will be needed to examine the
hydrolyzing activities and thus the functional importance of
such proteasomes.
Rammensee and coworkers [19] showed that the hydrolyz-
ing activities of yeast proteasome subunits as determined with
short substrates corresponded to a large extent with the cleav-
age site preferences in polypeptide substrates. This ¢nding was
unprecedented considering previous studies by Groettrup et
al. [12] demonstrating that the usage of speci¢c cleavage sites
in the pp89 polypeptide could not be assigned to single cata-
lytic subunits in the case of mammalian proteasomes. Further
studies using a larger set of polypeptides and di¡erent mutant
mammalian proteasomes will be needed to fully understand
the contribution of individual catalytic sites and of protea-
some structure to substrate cleavage. These investigations
are of functional importance in particular for the design of
drugs to interfere with speci¢c proteasome activities as de-
sired, for example, for therapy of CD8 T cell-mediated auto-
immune disease. In addition, they may help to predict protea-
some cleavage site usage, relevant for the development of
vaccines to induce T cell-mediated immunity.
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